XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 4.01%932.72M | -7.75%254.71M | -8.89%264.94M | -38.44%128.97M | 135.99%284.1M | 70.59%896.79M | 22.59%276.12M | 3.68%290.81M | 198.55%209.48M | -48.22%120.39M |
Net income from continuing operations | -15.37%551.31M | -31.09%158.28M | -16.66%136.48M | -2.93%133.32M | 2.11%123.23M | 79.90%651.47M | 168.25%229.68M | 27.67%163.76M | 524.36%137.35M | -33.17%120.69M |
Depreciation and amortization | 41.57%87.5M | 6.21%20.58M | 165.06%3.98M | 23.82%32.04M | 36.26%30.89M | 41.78%61.81M | 77.31%19.38M | -157.33%-6.12M | 2,247.72%25.88M | -2.25%22.67M |
Deferred tax | -156.19%-14.95M | -10.99%-20.18M | -164.65%-11.74M | -31.70%10.19M | -42.13%6.78M | 188.85%26.61M | 50.16%-18.18M | -53.64%18.16M | 183.63%14.92M | 178.98%11.71M |
Other non cash items | -79.67%2.02M | -207.58%-3.53M | 2,236.60%5.66M | -179.02%-3.69M | 60.26%3.59M | 41.93%9.93M | -41.71%3.29M | 19.94%-265K | 567.86%4.68M | 125.28%2.24M |
Change In working capital | 73.87%-34.72M | 148.95%19.59M | -86.44%2.66M | -231.89%-112.76M | 171.10%55.8M | 68.90%-132.86M | -373.19%-40.01M | -50.76%19.61M | 92.60%-33.98M | -30,286.15%-78.48M |
-Change in receivables | 72.27%-29.79M | 259.71%11.62M | 25.31%-12.74M | -478.48%-100.34M | 209.05%71.67M | -1,510.62%-107.41M | 46.70%-7.28M | -381.94%-17.06M | -232.94%-17.35M | -1,169.79%-65.73M |
-Change in payables and accrued expense | -57.61%-9.4M | 54.77%-9.8M | -106.21%-2.72M | 298.45%25.66M | 34.53%-22.54M | 98.74%-5.96M | -311.28%-21.66M | 401.42%43.69M | 101.43%6.44M | -38.44%-34.43M |
-Change in other current assets | 1.13%25.34M | 15.75%20.37M | -52.00%2.56M | -238.06%-4.71M | 655.23%7.12M | -57.95%25.06M | 202.01%17.6M | -77.03%5.33M | -2.24%3.41M | -104.74%-1.28M |
-Change in other working capital | 53.15%-20.87M | 90.90%-2.61M | 226.00%15.56M | -26.00%-33.36M | -101.98%-455K | -492.10%-44.54M | -718.18%-28.67M | -761.74%-12.35M | -345.98%-26.48M | 383.72%22.95M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 4.01%932.72M | -7.75%254.71M | -8.89%264.94M | -38.44%128.97M | 135.99%284.1M | 70.59%896.79M | 22.59%276.12M | 3.68%290.81M | 198.55%209.48M | -48.22%120.39M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 23.56%-58.54M | 74.26%-7.47M | -21.08%-12.36M | 27.96%-12.66M | -31.62%-26.05M | -6.80%-76.58M | -182.62%-29.01M | 71.58%-10.21M | -61.89%-17.58M | -34.99%-19.79M |
Capital expenditure reported | 24.97%-50.58M | 56.49%-7.57M | -4.32%-13.11M | 28.06%-12.67M | 13.15%-17.23M | -37.23%-67.41M | -61.76%-17.39M | -13.51%-12.56M | -82.57%-17.61M | -12.38%-19.84M |
Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | 54.96%-11.57M | ---- | ---- | ---- | ---- |
Net other investing changes | -431.94%-7.96M | 319.57%101K | -68.32%746K | -80.56%7K | -16,730.19%-8.81M | -22.74%2.4M | -109.41%-46K | 184.42%2.36M | 102.98%36K | -98.23%53K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 23.56%-58.54M | 74.26%-7.47M | -21.08%-12.36M | 27.96%-12.66M | -31.62%-26.05M | -6.80%-76.58M | -182.62%-29.01M | 71.58%-10.21M | -61.89%-17.58M | -34.99%-19.79M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -41.99%-758.3M | -25.23%-122.18M | 20.24%-241.48M | -576.88%-195.02M | -90.24%-199.62M | 22.51%-534.07M | -127.41%-97.56M | 2.62%-302.76M | 86.83%-28.81M | 10.02%-104.93M |
Net issuance payments of debt | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net common stock issuance | -37.80%-752.67M | -20.73%-122.05M | 18.91%-243.26M | -509.62%-198.77M | -67.64%-188.59M | -13.31%-546.2M | ---101.09M | -3.07%-300M | 82.93%-32.61M | ---112.5M |
Proceeds from stock option exercised by employees | -31.79%13.58M | 18.92%4.17M | 521.32%3.67M | -2.90%4.48M | -88.79%1.26M | -2.78%19.92M | -5.09%3.51M | 36.81%591K | -54.06%4.62M | 77.63%11.2M |
Net other financing activities | -146.78%-19.21M | -22,731.58%-4.3M | 43.39%-1.9M | 10.80%-735K | -238.51%-12.28M | 96.58%-7.79M | 100.04%19K | 83.46%-3.35M | 97.82%-824K | 97.05%-3.63M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -41.99%-758.3M | -25.23%-122.18M | 20.24%-241.48M | -576.88%-195.02M | -90.24%-199.62M | 22.51%-534.07M | -127.41%-97.56M | 2.62%-302.76M | 86.83%-28.81M | 10.02%-104.93M |
Net cash flow | ||||||||||
Beginning cash position | 50.64%862.44M | 21.01%855.53M | 14.34%837.79M | 60.51%914.93M | 50.64%862.44M | -29.80%572.52M | 80.93%707M | 57.97%732.69M | -37.54%570M | -29.80%572.52M |
Current changes in cash | -59.50%115.88M | -16.37%125.07M | 150.07%11.1M | -148.27%-78.72M | 1,448.00%58.44M | 221.67%286.14M | -13.09%149.55M | 66.59%-22.16M | 136.88%163.09M | -104.28%-4.34M |
Effect of exchange rate changes | -425.86%-12.32M | -348.13%-14.61M | 288.43%6.64M | 497.49%1.59M | -426.76%-5.95M | 148.43%3.78M | -39.27%5.89M | 47.51%-3.53M | 93.94%-399K | 143.36%1.82M |
End cash Position | 12.01%965.99M | 12.01%965.99M | 21.01%855.53M | 14.34%837.79M | 60.51%914.93M | 50.64%862.44M | 50.64%862.44M | 80.93%707M | 57.97%732.69M | -37.54%570M |
Free cash flow | 6.36%882.14M | -4.48%247.14M | -9.49%251.84M | -39.39%116.29M | 165.43%266.87M | 74.03%829.38M | 20.63%258.73M | 3.28%278.24M | 186.35%191.86M | -53.20%100.54M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |